rs113529636 - TAF4
Magnitude 4.5 · 1 study on file
Reported associations
-
Genetic analysis of elevated levels of creatinine and cystatin C biomarkers reveals novel genetic loci associated with kidney function - Unknown journal (n.d.) · Unknown authors · PubMed 39927731
ABSTRACT: Abstract The rising prevalence of chronic kidney disease (CKD), affecting an estimated 37 million adults in the United States, presents a significant global health challenge. CKD is typically assessed using estimated Glomerular Filtration Rate (eGFR), which incorporates serum levels of biomarkers such as creatinine and cystatin C. However, these biomarkers do not directly measure kidney function; their elevation in CKD results from diminished glomerular filtration. Genome-wide association studies (GWAS) based on eGFR formulas using creatinine (eGFRcre) or cystatin C (eGFRcys) have identified distinct non-overlapping loci, raising questions about whether these loci govern kidney function or biomarker metabolism. In this study, we show that GWAS on creatinine and cystatin C levels
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Diet
-
moderate dietary sodium intake Moderate
high sodium elevates blood pressure and stresses glomerular filtration; relevant given genetic predisposition to reduced eGFR
aim for less than 2300 mg sodium daily
Discuss with your doctor
-
kidney function assessment and monitoring plan Moderate
GWAS finding of reduced eGFR risk warrants clinical evaluation and personalized screening strategy
discuss with primary care physician or nephrologist if not yet evaluated
Lifestyle
-
maintain consistent hydration Moderate
adequate hydration supports glomerular filtration rate and kidney function
target pale yellow urine; drink water consistently throughout the day
Screening
-
kidney function panel Moderate
rs113529636 in TAF4 is associated with reduced eGFR; regular monitoring detects changes early
eGFR, serum creatinine, cystatin C annually per provider